Stockscreener 앱 받기
0.962
3.80%
-0.038
시간 외 거래:
.98
0.018
+1.87%
Biofrontera Inc 주식(BFRI)의 최신 뉴스
BFRI News | BIOFRONTERA INC (NASDAQ:BFRI) - ChartMill
BFRI: All proposals, including director elections and plan amendments, were approved by shareholders - TradingView
Number of shareholders of Biofrontera Inc. – BOATS:BFRI - TradingView
Biofrontera Inc. Warrants (BFRIW) Stall at $0.03 as Trading Range TightensVolatility Stop - newsline.com
BFRI Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock DeclinesHealthcare Earnings Report - newsline.com
BFRI Q1 2026 Earnings: Steep EPS Miss Weighs on Shares as Revenue Remains UnreportedGAAP Earnings Report - newsline.com
Medicure: Q1 Earnings Snapshot - AOL.com
Bio-Path: Q1 Earnings Snapshot - AOL.com
Biofrontera Earnings Call Highlights Growth And Risks - TipRanks
Biofrontera (BFRI) Q1 2026 Earnings Transcript - The Motley Fool
BFRI Q1 2026 Earnings: Wider-than-Expected Loss as Stock Rises on Strategic ProgressRevenue Miss Report - newsline.com
Number of shareholders of Biofrontera Inc. – NASDAQ:BFRIW - TradingView
PTA-News: Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FIRST QUARTER OF 2026 - TradingView
BFRI: Revenue and margins are rising as new indications and regulatory milestones drive future growth - TradingView
REX: Fiscal Q1 Earnings Snapshot - AOL.com
Squires Says Sun PGR Petition Denied For Not Naming Parent - Law360
Biofrontera Inc. Warrants (BFRIW) Surge Over 19% as Speculative Interest ReturnsInvestment Factor - The Legal Advocate
Ellomay: Q1 Earnings Snapshot - AOL.com
Biofrontera Inc. (BFRI) Edges Higher: A Small-Cap Biotech Finds Temporary FootingEntry Point Alerts - newsline.com
Biofrontera Inc. (BFRI) Faces Selling Pressure, Nearing Critical Support at $0.75TPO Profile - The Legal Advocate
BFRI Q1 2026 Earnings: Significant EPS Miss, Yet Stock Rises on Operating DisciplineMargin Improvement Report - newsline.com
BFRI Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin Amid No Reported Revenue - The Legal Advocate
Biofrontera (BFRI) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin as Stock RisesRising Community Picks - Newser
BFRI Q1 2026 Earnings: Wide EPS Miss Fails to Dampen Investor SentimentNegative Surprise Momentum - newsline.com
Biofrontera to present at Lytham Partners Spring 2026 Investor Conference on May 28 - Pluang
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 - The Manila Times
BFRI Downgraded by Benchmark -- Rating Maintained as Speculative Buy - GuruFocus
This Hanover Insurance Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Biofrontera stock rating cut to Speculative Buy by Benchmark - Investing.com
Benchmark Downgrades Biofrontera to Speculative Buy From Buy, Price Target is $3 - marketscreener.com
Benchmark Co. Maintains Biofrontera(BFRI.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Benchmark Downgrades Biofrontera to Speculative Buy From Buy, Price Target Is $3 - Moomoo
Biofrontera (BFRI) Climbs +1.45% — Resistance at $0.85 in Focus 2026-05-19Most Watched Stocks - newser.com
Biofrontera (BFRI) Q1 2026 Earnings: Miss Sparks ConcernRevenue Surprise History - newsline.com
Biofrontera (BFRI) Drops -0.63% — Key Support at $0.76 2026-05-18Box Spread - The Legal Advocate
Biofrontera (BFRI) Reports Strong Q1 Growth and Improved Profita - GuruFocus
Biofrontera posts strong 17% revenue growth but wider Q1 loss than expected - Pluang
Biofrontera Inc. 1Q 2026: Revenue $10.08M, EPS $(0.41) — 10-Q Summary - TradingView
Biofrontera (BFRI) Q1 2026: revenue up 17% but going concern and ITC hit - Stock Titan
Biofrontera targets cash flow breakeven in 2026 while aiming for 80%-85% gross margin - MSN
Biofrontera Inc. (BFRI) reports Q1 loss, beats revenue estimates - MSN
BFRI: Q1 2026 delivered 17% revenue growth, 80% gross margin, and major clinical pipeline progress - TradingView
Earnings call transcript: Biofrontera Q1 2026 sees gross margin leap - Investing.com
Earnings call transcript: Biofrontera Q1 2026 sees gross margin leap By Investing.com - Investing.com India
BFRI: Revenue up 17%, gross margin at 80%, and clinical pipeline advancing toward key milestones - TradingView
Biofrontera Inc. Reports 17% Revenue Growth and Improved Gross Margins in Q1 2026, Advances Dermatology Pipeline - Minichart
Transcript: Biofrontera Q1 2026 Earnings Conference Call - Benzinga
Biofrontera Q1 2026 Earnings Call Transcript - MarketBeat
Biofrontera Inc. (NASDAQ:BFRI) Reports Q1 2026 Revenue and EPS Miss, Stock Falls in Pre-Market - ChartMill
Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
BIOFRONTERA ($BFRI) Releases Q1 2026 Earnings - Quiver Quantitative
2.11%
자본화:
|
볼륨(24시간):